| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Third Rock Ventures LLC, a venture capital firm focusedon building healthcare companies, announced March 25 the final closing of FundIII, which raised $516 million in an oversubscribed fund. With Fund III, ThirdRock says it will continue to "execute on its strategy of launching, buildingand supporting transformative healthcare companies." 
 
The firm has raised more than $1.3 billion so farsince its founding, all for investments in healthcare companies and with aparticular emphasis on innovative product engines.
 
 
"Since 2007, it has been our mission to be thepreferred partner for entrepreneurs, investors, employees and industry to buildgreat companies that discover and develop breakthrough products that make adifference for patients," said Kevin Starr, a partner at Third Rock Ventures. "Ourfunding to date has enabled us to successfully seed, support or launch morethan 31 important healthcare companies. With Fund III we will continue on ourmission, launching up to 16 new companies focused on disruptive areas ofscience and medicine."
 
 
Many of Third Rock's portfolio companies havedeveloped as part of collaborations with industry partners, the venture capitalfirm notes, maintaining that this "collaborative company building approach"enables Third Rock to address the unprecedented demand in the healthcareindustry for innovative products.
 
 
"Our approach has always been to seek out andexplore unique collaborative models that are aligned with our mission andvision," said Mark Levin, a partner at Third Rock Ventures. "I am personallyexcited about the continued interest from our industry partners in working withThird Rock to identify new areas of exciting science and launch companiestogether through high-value strategic partnerships."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A doctor wearing blue gloves and a white lab coat with a stethoscope around their neck holds a rendering of a digestive system on a glass pane with a swirled blue background.

Connecting the gut and liver to enhance drug development

Explore how a dual-organ microphysiological system connects human gut and liver tissue to bridge gaps in predicting how drugs behave in the body.
A syringe draws liquid from a glass vial, with several glass ampoules reflected on a glossy surface in the background

Turning up the heat: thermal analysis for biotherapeutics

Explore essential thermal stability techniques to ensure the safety, quality, and efficacy of biologic drugs.
A 3D-rendered image of a pink and white twisted RNA strand floating against a green, blurred cellular background.

Cutting the time and cost out of plasmid generation

Discover a hassle-free path to obtaining long, complex plasmid DNA.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue